Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CCR8 Biologics Sequence Review Report 2026: C-C chemokine receptor type 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR9 Biologics Sequence Review Report 2026: C-C chemokine receptor type 9 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCRL2 Biologics Sequence Review Report 2026: C-C chemokine receptor-like 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCRL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR4 Biologics Sequence Review Report 2026: C-C chemokine receptor type 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR3 Biologics Sequence Review Report 2026: C-C chemokine receptor type 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR5 Biologics Sequence Review Report 2026: C-C chemokine receptor type 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CCR6 Biologics Sequence Review Report 2026: C-C chemokine receptor type 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR2 Biologics Sequence Review Report 2026: C-C chemokine receptor type 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR10 Biologics Sequence Review Report 2026: C-C chemokine receptor type 10 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TNFRSF11A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 11A Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF11A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TNFRSF25 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 25 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF25 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
TNFRSF19 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 19 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
500
501
502
503
504
>>
1905
>